Baxter to Expand Manufacturing Operations in Singapore

Baxter International has announced its plans to expand its existing Singapore manufacturing operations with the addition of a new bulk production facility for Advate [Antihemophilic Factor (Recombinant), Plasma/Albumin- Free Method] - the recombinant factor VIII (rFVIII) that is free of blood-based additives, for people living with hemophilia A.

The needs of the global hemophilia community are changing due to improving standards of care in emerging markets, increased prophylactic use of rFVIII therapies and the fact that the life expectancy for hemophilia patients has increased from 11 years prior to the 1960s to more than 60 years today.

The company plans to enhance its manufacturing capabilities in Woodlands, Singapore.